MUC1 and neoplasm: demonstrated that recombinant chimeric norovirus-like particles (VLPs) combined with MF59 adjuvant effectively induced high-titer IgG antibodies targeting MUC1 in mice, which specifically recognize and target MUC1 on tumor cell surfaces, thereby enhancing immune recognition and clearance of tumors (163).